Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.

Biotecnología

Mr. Phillip  Hains B Bus, C.A., CA, M.B.A., MBA

Sec.

Mr. Eliot  Bourk

Chief Bus. Officer & Head of External Innovation

Ms. Jennifer  Chow

Chief Executive Officer, MD & Director

Dr. Li  Ren

Vice President of Technical Operations

Mr. Jason B. Litten M.D.

Chief Medical Officer

Mr. Kelly R. Thornburg

Vice President & Head of Quality

Mr. Nathan  Jong C.A.

Company Sec.

Nombre	Capitalización
hVIVO plc	0M
VistaGen Therapeutics, Inc.	0M
Exopharm Limited	0M
Yunnan Botanee Bio-Technology Group Co.LTD	0M
BioVaxys Technology Corp.	0M
MedMira Inc.	0M
Regenicin, Inc.	0M
Vascular Biogenics Ltd.	0M
CorMedix Inc.	0M
Wave Life Sciences Ltd.	0M

Chimeric Therapeutics Limited

Chimeric Therapeutics Limited Lista de competidores

Principales competidores